MDxHealth (MDXH) Q1 2026 Earnings Transcript

MDxHealth reported pro forma Q1 core revenue of $23.9 million, up 11%, but pro forma gross margin fell to 62.9% from 68.0% and the operating loss widened to $7.9 million. The company is exiting its Resolve UTI business and Plano lab operations after a $10.4 million Novitas recoupment demand and reimbursement uncertainty, while raising 2026 core revenue guidance to $110 million-$115 million. Management is refocusing on prostate cancer diagnostics and AI initiatives, but near-term litigation, restructuring, and volume risks remain.

Analysis

MDXH is doing the hardest thing in medtech: shrinking the business to improve the earnings quality narrative. The strategic exit removes a reimbursement landmine, but the bigger second-order effect is that it de-risks the company’s sales motion by eliminating a low-ROI distraction that was consuming reps, incentive comp, and management bandwidth. That should help the core prostate franchise, but only if the organization can convert freed-up selling time into faster tissue and liquid utilization within the next 2-3 quarters; otherwise, the market will treat the reset as revenue destruction masked as focus.

The Novitas recoupment demand is the real overhang, not because the dollar amount is existential today, but because it raises the probability of a multi-quarter legal/accounting noise cloud and a higher cost of capital. Even if management wins on appeal, the decision to close the business signals they no longer want to underwrite payer optionality in a jurisdiction-dependent model, which likely makes investors assign a lower terminal multiple to any remaining reimbursement-sensitive revenue streams. The balance-sheet cushion looks adequate for now, but that cushion is smaller after the earn-out payment and could be stressed if restructuring cash costs front-load faster than operating efficiencies show up.

The AI angle is more important strategically than financially near term. In diagnostics, “AI-enabled” is still mostly a marketing phrase, but if MDXH can use it to improve pathologist workflow, customer retention, or assay attachment rates, it could modestly widen the moat in the tissue business over 12-18 months. That said, AI will not offset execution risk in the next two quarters; the stock will trade primarily on whether sequential volumes inflect and whether gross margin stabilizes after the mix shift.

Consensus may be underestimating how much of the remaining core story depends on two fragile assumptions: that tissue volumes re-accelerate quickly and that the post-Resolve sales organization can absorb the transition without meaningful churn. If either fails, the market will likely re-rate MDXH as a small-cap turnaround with litigation overhang rather than a focused growth urology platform. The asymmetry is that a clean legal resolution plus two quarters of visible volume improvement could drive a sharp multiple expansion off a compressed base, but absent that, the downside is a slow bleed in confidence rather than a single event-driven drop.

Key Decisions for Investors

• Avoid initiating a fresh long MDXH position for now; wait 1-2 quarters for evidence that tissue volumes inflect and the Novitas issue stops worsening. Risk/reward is poor until the market sees proof that the strategic reset is accretive rather than merely cleaner.
• If already long MDXH, reduce size by 25-50% and hold only as a catalyst-driven turnaround with a 6-9 month horizon. Add back only if sequential core revenue accelerates and gross margin stabilizes above the low-60s.
• Consider a hedged long EXAS / short MDXH pair for the next 3-6 months. EXAS can benefit indirectly from share shift and digestion of the ExoDx ecosystem while MDXH carries payer/legal and execution overhang; the spread favors the higher-quality balance sheet and cleaner reimbursement profile.
• For more aggressive accounts, trade MDXH via options: buy 3-6 month puts or put spreads into any post-call bounce. The thesis is that the stock can overshoot on “focus story” headlines before the market prices in restructuring cash burn and litigation uncertainty.
• Set a trigger to revisit long MDXH only after two data points: one quarter of sequential tissue growth and a formal update on the Novitas appeals path. Without both, the probability-weighted upside is not attractive enough to justify underwriting the noise.